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Electrophysiology Testing to Stratify Patients With Left Bundle Branch
Block After Transcatheter Aortic Valve Implantation
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Gregor Fahrni, MD; Raban Jeger, MD; Christoph Kaiser, MD; Stefan Osswald, MD; Christian Sticherling, MD; Michael K€uhne, MD
Background-—Left bundle branch block (LBBB) is common after transcatheter aortic valve implantation (TAVI) and is an indicator of
subsequent high-grade atrioventricular block (HAVB). No standardized protocol is available to identify LBBB patients at risk for
HAVB. The aim of the current study was to evaluate the safety and efficacy of an electrophysiology study tailored strategy in
patients with LBBB after TAVI.
Methods and Results-—We prospectively analyzed consecutive patients with LBBB after TAVI. An electrophysiology study was
performed to measure the HV-interval the day following TAVI. In patients with normal His-ventricular (HV)-interval ≤55 ms, a loop
recorder was implanted (ILR-group), whereas pacemaker implantation was performed in patients with prolonged HV-interval
>55 ms (PM-group). The primary end point was occurrence of HAVB during a follow-up of 12 months. Secondary end points were
symptoms, hospitalizations, adverse events because of device implantation or electrophysiology study, and death. Of 373 patients
screened after TAVI, 56 patients (826 years, 41% male) with LBBB were included. HAVB occurred in 4 of 41 patients (10%) in the
ILR-group and in 8 of 15 patients (53%) in the PM-group (P<0.001). We did not identify other predictors for HAVB than the HV
interval. The negative predictive value for the cut-off of HV 55 ms to detect HAVB was 90%. No HAVB-related syncope occurred in
the 2 groups.
Conclusions-—An electrophysiology study tailored strategy to LBBB after TAVI with a cut-off of HV >55 ms is a feasible and safe
approach to stratify patients with regard to developing HAVB during a follow-up of 12 months. ( J Am Heart Assoc. 2020;9:
e014446. DOI: 10.1161/JAHA.119.014446.)
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T he transcatheter aortic valve implantation (TAVI) proce-dure is an established therapy for patients with severe
aortic stenosis with high or intermediate surgical risk.1,2
TAVI has been shown to reduce all-cause mortality, cardiac
symptoms, and re-hospitalization compared with medical
therapy.3 However, high-grade atrioventricular conduction
disturbances (ie, second-degree atrioventricular block Mobitz
type 2 or complete atrioventricular block) requiring perma-
nent pacemaker implantation remain a common problem
after TAVI and are observed in 10% to 20% of patients.4 Even
more commonly, incomplete conduction disturbance such as
left bundle branch block (LBBB) develop and have been
reported to occur in 1 quarter of patients.5 Data on the
impact of LBBB after TAVI on progression to complete
atrioventricular block are scarce and inconsistent.6,7 How-
ever, patients with persistent LBBB after TAVI have been
shown to have a high incidence of syncope in 16% of
patients and complete atrioventricular block in 20% of the
patients.8 Furthermore, a decrease in left ventricular ejection
fraction and a poorer functional status was observed during
1-year follow-up in patients with LBBB after TAVI.8 Progres-
sion from LBBB to atrioventricular block does not necessarily
occur in the peri-interventional period, but can occur later
after TAVI.9 According to current guidelines, the significance
of LBBB in patients after TAVI remains unclear.4 Therefore,
the treatment of patients with LBBB after TAVI is currently
tailored individually (eg, based on PR-interval and/or QRS
duration) leading to marked differences in clinical manage-
ment.10
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Because the level of the conduction disturbance is
associated with progression to atrioventricular block, electro-
physiology testing can be used to characterize atrioventric-
ular-conduction behavior, allowing conduction disturbances to
be classified as supra- or infranodal by measuring Atrial–His
(AH) and His-Ventricular (HV) intervals.11 The aim of the
current study was to prospectively evaluate a tailored
management strategy based on a simple HV-interval mea-
surement in patients with LBBB after TAVI. The efficacy and
safety of this approach were assessed based on the
prediction of progression to high-grade atrioventricular block
(HAVB) as well as symptoms, mortality, hospitalizations, and
complications.
Methods
Study Design
In this prospective study, all patients undergoing TAVI were
screened for LBBB. Patients with both, new-onset LBBB after
TAVI and pre-existing LBBB before TAVI were included in the
analysis. Exclusion criteria for the analysis were pre-existing
high-grade atrioventricular block or high-grade atrioventricu-
lar-block directly after TAVI requiring pacemaker implantation,
a previously implanted pacemaker, and a nontransfemoral
implantation route.
The self-expandable Evolut R and Evolut R Pro (Medtronic,
Minneapolis, MN), Portico (St. Jude Medical, St Paul, MN), and
the Acurate NEO (Boston Scientific, Natick, MA), the balloon-
expandable Sapien 3 (Edwards Life Science, Irvine, CA), or the
mechanically expandable Lotus (Boston Scientific Inc., Marl-
borough, MA) were used. Informed consent was obtained
from all patients and the study was approved by the local
ethics committee for Northwest/Central Switzerland. The
data that support the findings of this study are available from
the corresponding author upon reasonable request.
Transcatheter Aortic Valve Implantation
Patients with severe symptomatic aortic stenosis and an
indication for valve replacement were considered for TAVI if
there was an intermediate or high surgical risk. All patients
underwent transthoracic echocardiography, coronary angiog-
raphy, and ECG-triggered multislice computed tomography
scan of the aorta for procedural planning. Valve implantation
was performed according to the individual specific manufac-
turer’s recommendations. In general, patients underwent
predilatation of the stenosed aortic valve with a balloon that
was at least 2 mm smaller than the annulus size. After
implantation of the TAVI prosthesis, supravalvular angiogra-
phy was performed to check for paravalvular leakage. In case
of intermediate or severe paravalvular leakage, postdilatation
was performed with a balloon with the same size as the
annular diameter measurement. During the procedure, all
patients received a temporary pacemaker using a quadripolar
catheter (5 F, Supreme JSN, St. Jude Medical, Minnetonka)
positioned in the right ventricular apex. After the procedure,
patients were transferred to the coronary care unit overnight
with the temporary pacemaker left in place and programmed
to VVI 30 bpm. Continuous rhythm monitoring by telemetry
was performed for 72 hours. All patients were treated with
clopidogrel 75 mg daily for 3 months in addition to the
baseline medication.
Electrocardiographic Assessment
A 12-lead ECG assessment was performed the day before, the
day of, and the day after the TAVI procedure using a standard
recorder (Schiller, Baar, Switzerland). Characterization of the
ECG to identify complete LBBB was performed based on the
ECG acquired the day after the procedure using the de Luna
criteria.12
Electrophysiology-Tailored Management Strategy
In patients with newly developed or pre-existing ECG-
documented LBBB the day after TAVI, a limited electrophys-
iology study (EPS) was performed within 24 hours of the
procedure. For the purpose of obtaining intracardiac mea-
surements, the quadripolar diagnostic catheter used as a
temporary pacemaker wire (5 F, Supreme JSN, St. Jude
Medical) during TAVI was retracted from the apex and
Clinical Perspective
What Is New?
• We showed that an intracardiac His ventricular-interval
measurement in patients with left bundle branch block after
transaortic valve implantation stratifies patients at risk for
high-grade atrioventricular block.
• With the His ventricular cut-off of 55 ms, we safely
identified patients who did not develop high-grade atrioven-
tricular block when presenting with a left bundle branch
block after transaortic valve implantation with a negative
predictive value of 90%.
What Are the Clinical Implications?
• This electrophysiology-tailored management strategy helps
to identify patients with left bundle branch block who will
not develop high-grade atrioventricular block.
• Consequently, it offers a potential safe and efficient way to
manage patients with left bundle branch block after
transaortic valve implantation.
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positioned at the His bundle to measure AH- and HV-intervals.
In addition, baseline electrophysiological parameters (PR
duration, QRS duration) were assessed in a systematic
fashion. Based on the mean HV-interval of 3 measurements,
patients were categorized into 2 arms: (1) In patients with a
prolonged HV >55 ms, pacemaker implantation was
performed immediately after the measurement (pacemaker-
group). (2) Patients with an HV-interval ≤55 ms were mon-
itored according to our clinical standard on telemetry for
72 hours after TAVI and if no conduction disturbance
requiring pacemaker implantation was recorded during the
monitoring period, an implantable loop recorder (ILR, Reveal
LINQTM; Medtronic, Minneapolis) with remote monitoring
capabilities was implanted (ILR-group).
Pacemaker Implantation and Programming
In patients with a prolonged HV-interval (>55 ms), pacemaker
implantation was performed by a trained electrophysiologist
in a standardized fashion using a left-sided approach and an
axillary vein puncture or cephalic vein cut-down for vascular
access. The right ventricular lead was placed in an apical
position or in a septal position if the apical position showed
inadequate measurements for sensing or threshold. If an atrial
lead was implanted, it was positioned in the right atrial
appendage. DDD-, VDD-, or VVI-pacemakers were used at the
physicians’ discretion. The lower rate was programmed to
40 bpm and unnecessary right ventricular pacing was avoided
by programming long atrioventricular-intervals or specific
algorithms (eg, AAI-DDD).
ILR Implantation and Programming
A validated ILR (Medtronic Reveal LINQ) was implanted by a
trained cardiologist in a standardized manner in order to
minimize artifacts and to maximize signal quality. The device
was implanted 2 cm left of the sternum at an implantation
angle of 45 at the level of the fourth or fifth intercostal space.
The device pocket was created using the insertion tool.
Bradycardia detection was programmed to 40 bpm. Pause
detection was programmed to 4.5 s. Atrial fibrillation detec-
tion was programmed to “AF only”.
End Points
The primary end point of the study was the occurrence of
HAVB (second-degree atrioventricular-block Mobitz type 2 or
complete atrioventricular block) documented on a 12-lead
ECG and/or the implantable loop recorder (ILR-group) or
documentation of HAVB on a 12-lead ECG and/or necessity of
ventricular pacing >1% (pacemaker-group) during a follow-up
of up to 12 months. Necessity of pacing was defined by the
cumulative need for ventricular pacing extracted from the
device during pacemaker interrogation at the 3-, 6-, and 12-
month follow-up visits. A rhythm strip with a duration of at
least 1 minute was recorded during all follow-up visits with
the device programmed to VVI mode at a rate of 30 bpm.
Secondary end points were symptoms (dizziness, syncope),
death (all-cause and cardiovascular mortality), rehospitaliza-
tion for cardiovascular events, and adverse events caused by
device implantation or because of the electrophysiology study
(pneumothorax, bleeding, perforation, mechanical atrioven-
tricular-block, death, or other).
Follow-Up
Follow-up was scheduled 3, 6, and 12 months after TAVI and
included physical examination, 12-lead ECG, transthoracic
echocardiography, and pacemaker interrogation. ILR follow-up
was performed via remote monitoring using the Medtronic
Carelink system. Minimal follow-up duration was 6 months.
Statistical Analysis
Continuous variables are presented as mean1 SD in
combination with the median. For continuous variables,
comparisons were made using Student t test, or Mann–
Whitney U test, as appropriate. Discrete variables were
compared using Fisher exact test. An intention-to-treat
analysis was performed. Exact logistic regression to deter-
mine univariate predictors for the occurrence of HAVB was
performed. Receiver-operating characteristic curves were
constructed to identify the optimal threshold (cut-off value)
aiming to identify patients with risk of HAVB with a high
specificity and the area under the curve was calculated. For
sensitivity analysis of each patient on the results, we
performed a leave-1-out analysis for the primary results, the
exact logistic regression, and the area under the curve. A
P<0.05 was considered statistically significant. Analyses were
performed using SPSS (IBM SPSS Statistics for Windows,
Version 22.0; Armonk).
Sample-size calculation was performed before the study,
assuming a 1-year incidence of the primary end point of HAVB
of 33% with HV >55 ms and 5% among those with HV
≤55 ms. This resulted in a calculated sample size of 56
patients with LBBB block to have 80% power at an a level of
0.05 to show a significant between-group difference.
Results
Of 373 TAVIs performed at our tertiary referral center,
implantation was performed using a transfemoral approach in
315 patients. Excluding patients with a previously implanted
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pacemaker and patients with HAVB after TAVI requiring direct
pacemaker implantation resulted in a set of 257 patients. Of
these, 78 patients (21%) were found to have LBBB (new-onset
or pre-existing) the day after TAVI. Of the 78 patients, 56 gave
written informed consent and were included in the analysis.
The flowchart of the study is shown in Figure 1.
Baseline characteristics of the 56 patients studied for this
analysis are shown in Table 1. The Sapien 3, Portico, Acurate
NEO, Evolut R/Pro, and Lotus valvewere implanted in16patients
(29%), 16 patients (29%), 2 patients (4%), 2 patients (4%), and 20
patients (36%), respectively. Mean follow-up was 123 months.
Of the 56 patients, 42 had new-onset LBBB (75%) after TAVI and
14patients (25%) had pre-existing LBBB. Therewas no significant
difference in any of the baseline parameters between patients
with new-onset and pre-existing LBBB.
During EPS, 41 patients (73% [95% CI 60–84%]) showed a
normal HV-interval ≤55 ms. One patient with a HV of 61 ms
declined pacemaker implantation but remained in the pace-
maker-group according to the intention-to-treat analysis. In
the pacemaker-group a DDD, VDD, or VVI pacemaker was
implanted in 6 (43%), 5 (36%), and 3 (21%) patients,
respectively. Findings from 12-lead ECG and intracardiac
measurements of the 2 groups are shown in Table 2.
Of note, LBBB resolved in 7 of 56 patients (13%) within
3 months of follow-up. LBBB resolved in 6 of 41 (15%)
patients in the ILR-group and 1 of 15 (7%) patients in the
pacemaker group (P=0.661 between groups).
Primary End Point
During follow-up, HAVB occurred in 12 of 56 patients overall
(21% [95% CI 12–34%]) (Table 3). In the ILR-group, HAVB
requiring subsequent pacemaker-implantation occurred in 4
of 41 patients (10% [95% CI 3–23%]) compared with 8 of 15
patients (53% [95% CI 27–79%]) with HAVB in the pacemaker-
group (P=0.001) with 1 implantation in the ILR group within
the 72 hours of telemetric monitoring. These numbers were
not materially changed in the leave-1-out analysis. Details for
the pacemaker indication of the 4 patients in the ILR-group
are summarized in Table 4.
There was no statistically significant difference in any of
the baseline parameters shown in Table 1 (baseline, prein-
terventional echocardiography, and electrocardiography) of
the patients with or without postprocedural HAVB in the ILR-
group. Similarly, in the pacemaker-group, there was no
difference in any of the baseline parameters between the
Figure 1. Flow chart of the total cohort. AVB indicates atrioventricular block; HV, His-Ventricular; LBBB,
left bundle branch block; PM, pacemaker.
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patients with or without postprocedural HAVB, except for age
(874 years versus 784 years; P=0.001).
Secondary End Points
Symptoms such as dizziness or syncope after the implanta-
tion were observed overall in 10 patients. The symptoms were
not caused by HAVB as confirmed by pacemaker and ILR
interrogation.
During the follow-up period of 12 months, all-cause mortal-
ity was 11% (6 patients), with 3 of 40 (7.5%) patients in the ILR-
group and 3 of 16 (19%) in the pacemaker-group (P=0.094).
Three patients died of cardiovascular causes (progression of the
heart failure [n=2], embolic stroke [n=1]), whereas the other 3
died from noncardiac causes. Rehospitalizations for any reason
during the follow-up period were observed in 20 of 56 (36%)
patients, with 3 of 16 (19%) in the pacemaker-group and 17 of
40 (43%) in the ILR-group (P=0.127) (Table 4). No difference in
any of the baseline or interventional parameters could be
observed between patients with or without hospitalization
during follow-up. No adverse event caused by device implan-
tation or EPS was observed in any of the patients.
Incidental Findings on ILR or Pacemaker
Interrogation
During follow-up, 4 of 41 patients (13%) in the ILR-group were
found to have symptomatic SND 1.5, 3, 3 and 5 months after
TAVI, leading to pacemaker implantation. In addition, a first
diagnosis of AF was made in five of 41 (12%) patients in the
ILR-group and one of 15 (7%) patients in the pacemaker-group
(P=0.66). Finally, episodes of nonsustained VT were observed
in 4 patients (3 ILR-group, 1 pacemaker-group).
Retrospective Verification of HV-Interval Cut-Off
Exact logistic regression (using the baseline data) identified the
HV-interval as the parameter to predict HAVB (odds
ratio=1.111 per unit increase [95% CI 1.039–1.204];
P=0.001) (Table S1). Area under the receiver-operating char-
acteristic curve for HAVB was 0.792 (95% CI 0.646–0.937)
(Figure 2). These results were not materially changed in the
leave-one-out analysis. With the pre-defined cut-off value of HV
55 ms, the sensitivity and specificity to identify HAVB was 67%
(8 of 12 patients) and 84% (37 of 44 patients), respectively. The
positive predictive value (PPV) and negative predictive value
(NPV) was 53% (8 of 15) and 90% (37 of 41), respectively.
Importantly, non-invasive electrocardiographic parameters (PR-
interval, QRS duration) were not predictive for HAVB after TAVI.
Of note, analyzing patients with new-onset LBBB only, HV-
interval remained the only significant parameter to predict
HAVB (odds ratio=1.153 [95% CI 1.046–1.271]; P=0.004) and
there was no significant difference between the subgroups with
new-onset compared with pre-existing LBBB.
Discussion
Despite being one of the most common complications of TAVI,
the clinical implication and particularly the management of
Table 1. Baseline Data
N=56
Baseline
Age, y 826 (83)
Male sex 23 (41%)
Height, cm 16413 (165)
Weight, kg 7725 (73)
BMI, kg/m2 276 (26)
Hypertension 35 (63%)
CAD 30 (54%)
Dyslipidemia 27 (48%)
Diabetes mellitus 13 (23%)
Smoker
No 46 (82%)
Yes 3 (6%)
Former 7 (13%)
AF 22 (39%)
NYHA
I 3 (5%)
II 19 (34%)
III 30 (54%)
IV 4 (7%)
Preinterventional echocardiography
DPmean, mm Hg 4815 (48)
Aortic valve area, mm2 0.70.2 (0.7)
LVEF, % 5311 (55)
Electrocardiography
PR-interval, ms 18635 (180)
QRS-interval, ms 10227 (94)
Atrioventricular conduction
AVBI 8 (14%)
AVBI & LBBB 4 (7%)
LBBB 14 (25%)
RBBB 0
Data are presented as meanSD (median) for continuous variables and as n (%) for
categorical variables. AF indicates atrial fibrillation; AVBI, AV block I; BMI, body mass
index; CAD, coronary artery disease; DPmean, mean transvalvular pressure gradient;
LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; NYHA, New York
Heart Association; RBBB, right bundle branch block.
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patients with LBBB after TAVI are still uncertain.4 To the best
of our knowledge, this is the first study prospectively
assessing a tailored management strategy based on electro-
physiology testing for the management of LBBB after TAVI.
During follow-up, the occurrence of HAVB, reflected by the
need for pacing in the pacemaker-group and documentation
of HAVB in the ILR-group, was determined based on
continuous rhythm monitoring from ILRs and PMs.
The main findings of this study are the following: (1) The
presented approach using EPS with the temporary pacemaker
lead (used during the TAVI procedure) to measure the HV-
interval (cut-off for HV >55 ms) is feasible and safe. (2) HAVB
was observed in 56% of patients with HV >55 ms and 10% of
patients with HV ≤55 ms. (3) No syncope caused by HAVB
was observed in any patient during follow-up. (4) The cut-off
value of HV >55 ms identifies patients with subsequent HAVB
with a sensitivity of 67% and specificity of 84%. (5) The
important implication for clinical practice is that the negative
predictive value of the HV cut-off of 90% allows identifying
patients with LBBB after TAVI who are at low risk of
developing HAVB.
Current Strategies for Patients With LBBB
Because of the lack of guidelines, the management of patients
with LBBB after TAVI varies greatly, and indications for
Table 2. Electrocardiographic Characteristics After TAVI
During Electrophysiology Testing
Baseline Overall ILR-Group PM-Group P Value
Patients 56 41 (73%) 15 (27%)
Diagnosed
AF
21 (38%) 15 (38%) 7 (44%) 0.665
RR interval 793155 (770) 785171
(769)
82183
(829)
0.421
AH, ms 11238 (108) 11641
(110)
10026
(96)
0.213
HV, ms 5311 (52) 485 (48) 678 (65) <0.001
PR, ms 19943 (190) 19846
(190)
20231
(192)
0.741
QRS, ms 15016 (150) 15015
(150)
15020
(150)
0.824
Data are presented as meanSD (median) for continuous variables and as n (%) for
categorical variables. AH and PR could only be measured in n=46 patients because of AF
during EPS. AF indicates atrial fibrillation; AH, Atrial His; EPS, electrophysiology study;
HV, His Ventricular; ILR, implantable loop recorder; PM, pacemaker; TAVI, transcatheter
aortic valve replacement.
Table 3. Details of HAVB During Follow-Up in Patients of the ILR-Group
Patient Indication for PMI
New
Onset LBBB
Time to Event
After TAVI
(Days) Sex
Age
(Years) Valve Type
Cardiac
Symptoms HV (ms) PR (ms) QRS (ms)
Pacing
During FU
1 AVBIII Yes 3 f 78 Sapien 3 Dizziness 44 190 154 100%
2 Paroxysmal AVBIII Yes 7 f 75 Portico No 52 214 160 2%
3 Paroxysmal AVBIII
(single episode)
Yes 8 f 90 Lotus No 55 190 152 0%
4 Intermittent AVBII
Mobitz type 2
No 158 m 76 Sapien 3 No 48 290 162 33%
AVBII indicates AV block II; AVBIII, AV block III; f, female; FU, follow-up; HV, His-ventricular; HAVB, high-grade atrioventricular block; ILR, implantable loop recorder; LBBB, left bundle branch
block; m, male; PMI, pacemaker implantation; TAVI, transcatheter aortic valve replacement.
Table 4. Summary of Primary and Secondary End Points for
the 2 Groups
ILR-Group (n=41) PM-Group (n=15)
Primary
HAVB 4 (10%) 8 (53%)
Secondary
Symptoms
Syncope 3 (8%) 0
Dizziness (noncardiac) 6 (15%) 1 (6%)
Death 3 (8%) 3 (19%)
Hospitalizations 17 (42%) 3 (19%)
HAVB 3 0
SND 4 0
Symptomatic AF 2 0
Dizziness or
syncope (noncardiac)
3 0
Dizziness or
syncope (cardiac)
1 (VT) 0
Cardiac decompensation 2 1
Other 2 2
Cause of death: (1) in ILR group: 1 sepsis after knee replacement, 1 intracerebral
cerebral hemorrhage, 1 embolic stroke. (2) in PM-group: 2 heart failure; 1 suspected
pneumonia. HAVB indicates high-grade AV block; ILR, implantable loop recorder; PM,
pacemaker; SND, sinus node dysfunction; VT, ventricular tachycardia.
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pacemaker implantation are mainly based on 12-lead ECG
measurements. For periprocedural new-onset LBBB, Auffret
et al proposed a management strategy based on 24-hour
monitoring in the intensive care unit.13 If LBBB persisted more
than 48 hours after TAVI, pacemaker implantation was
considered if the QRS duration was ≥160 ms or in the
setting of first-degree AVB and a QRS duration between 130
and 160 ms. QRS duration and PR-interval was also used in
decision making for pacemaker implantation by Roten et al
who proceeded to pacemaker implantation in case of
increasing PR-interval or increasing QRS duration in the
setting of LBBB after TAVI.10 However, the PR-interval cannot
be measured in patients with AF, and AF was present in 18%
of patients during EPS in our study population. In addition, in
contrast to this empirical practice, our data show that neither
QRS duration nor PR-interval were predictive of HAVB in
patients with LBBB after TAVI, but the measurement of the
HV-interval was.
Tovia-Brodie et al reviewed patients undergoing EPS
because of new-onset LBBB, pre-existing or new-onset LBBB
associated with a PR-interval increase of >20 ms with TAVI, or
pre-existing or new-onset LBBB and “slow” AF.14 EPS was
performed at a median of 6 days after TAVI, but no TAVI-
specific protocol was in place. Indication for pacemaker
implantation was the presence of severe infranodal conduc-
tion disturbance (HV-interval ≥75 ms or occurrence of
second-degree infranodal block during incremental pacing
<400 ms), which resulted in a pacemaker implantation rate of
31%. This is comparable to a recent retrospective study by
Rogers et al, who reported a pacemaker implantation rate of
30% in patients undergoing EPS including a procainamide
challenge and any conduction disturbance but no clear
indication for pacemaker implantation.15 In our study using
a standardized management strategy, we report a similar
pacemaker implantation rate based on EPS of 29% in new-
onset and pre-existing LBBB using the cut-off of 55 ms for the
HV-interval. In addition, in an analysis of a general TAVI
population not specifically studying LBBB, prolongation of the
HV-interval by more than 13 ms after TAVI was also identified
as a predictor of HAVB, emphasizing the importance of the
HV-interval measurement as a predictor of HAVB.16 In our
study, we used the absolute HV-interval value as a single and
simple measure determined only in patients with LBBB after
TAVI.
Finally, in previous studies, only parameters associated
with “the need for pacemaker implantation” were investi-
gated. However, the “need for pacemaker implantation”
because of an individual pacemaker indication is obviously
not synonymous with the actual “need for pacing” because of
HAVB. In addition, even if pacemaker implantation was strictly
limited to patients with HAVB after TAVI, absence of “need for
ventricular pacing” during follow-up has been observed in a
relevant proportion of patients.17 To address this uncertainty,
we quantified the amount of ventricular pacing from pace-
maker interrogation. We defined HAVB in the pacemaker
group based on the documentation of HAVB on 12-lead ECG,
but also the real need for pacing during follow-up. In addition,
in order to document new-onset rhythm disturbances after
TAVI, we implanted ILRs in all patients with LBBB after TAVI
and a normal HV-interval. This allowed a detailed rhythm
analysis also in patients with LBBB after TAVI but no
pacemaker in addition to the systematic reporting of clinical
events (eg, syncope).
Another prospective study investigating patients with LBBB
after TAVI by performing EPS is being conducted using a less
strict HV-interval cut-off value for pacemaker implantation of
70 ms, but this study is currently still ongoing.18
Definition of HAVB
HAVB is simple to diagnose in the ILR-group but more difficult
to ascertain in the pacemaker-group. In order not to miss any
HAVB, we followed 2 different strategies during pacemaker
interrogation: (1) a rhythm strip was recorded for at least
1 minute with a programmed pacing rate of 30 bpm in VVI
mode. Using that strategy, only persistent HAVB can be
found. (2) The percentage of pacing recorded in the
pacemaker over the entire follow-up period was extracted.
Of note, specific algorithms (eg, AAI-DDD) were used to
prevent unnecessary right ventricular pacing and the lower
rate limit was programmed to 40 bpm. Using a cut-off of 1%
Figure 2. Receiver-operating characteristics curve demonstrat-
ing the accuracy of His-Ventricular measurement for high-grade
atrioventricular block. AUC indicates area under the curve.
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of need for pacing, the rate of HAVB might be overestimated.
Nevertheless, 1% pacing corresponds to a mean of 15 min-
utes of pacing per day, which might be clinically relevant to
prevent syncope (secondary study end point). Therefore, even
when using a cut-off of 1% pacing, some episodes of
paroxysmal HAVB may be missed.
Safety
The presented approach for HV measurements using the
temporary pacing lead in patients with LBBB after TAVI does
not require a new vascular access and consequently does not
increase the risk of additional access complications. We did
not observe any periprocedural complications of this EPS-
based management strategy, neither because of the addi-
tional ILR nor because of pacemaker implantation. However,
when widely adopted, the strategy may be associated with
device-related complications.4
Whereas the number of events for the primary outcome of
HAVB was overall in the expected range, there were
numerically more secondary end points in the ILR-group.
However, this difference was not statistically significant and
mainly because of the occurrence of symptomatic sinus node
disease and HAVB requiring pacemaker implantation, AF-
related symptoms, and the occurrence of syncope or dizziness
because of noncardiac causes. Whereas hospitalizations
because of newly developed HAVB or SND requiring pace-
maker implantation obviously did not occur in the pacemaker-
group, it is conceivable that a referral bias is present because
patients with a pacemaker are probably less likely to be
referred when they report dizziness or syncope, or AF-related
symptoms. It is important to note that no cardiac syncope
because of bradycardia was observed in any of the patients
during follow-up compared with the 16% reported by Urena
et al8 in patients without pacemaker implantation.
Clinical Implication
Using the proposed management strategy of performing a
simple HV-interval measurement with the temporary pace-
maker wire in patients with LBBB after TAVI, clinicians can
safely identify patients with LBBB who will not develop HAVB
with a negative predictive value of 90% based on the HV cut-
off of 55 ms. Therefore, HV cut-off based pacemaker
implantation offers a safe and efficient way to treat patients
with LBBB after TAVI.
Limitations
This is a relatively small single-center study with 373 patients
screened, resulting in 56 patients with LBBB after TAVI being
analyzed. This was addressed by dedicated statistical analysis
and critical interpretation of the results. Whether the
presented observations can be applied to a general TAVI
population with LBBB after the procedure needs further
confirmation in larger trials.
Another limitation is the primary end point definition of
HAVB. The 1% cut-off regarding necessity of ventricular pacing
as a sign of HAVB is arbitrary and debatable. In the absence of
evidence and recommendations, we used a conservative cut-
off. Based on the cut-off of 1% need for pacing for the
definition of HAVB in the pacemaker-group, the occurrence of
HAVB might be overestimated. On the other hand, some short
paroxysmal episodes might still have been missed.
For classification of LBBB, we chose to use the de Luna
criteria as opposed to the stricter Strauss criteria.12,19 In
contrast to previous studies, we included not only patients with
new-onset LBBB but also patients with pre-existing LBBB. The
rationale behind this was to evaluate a universal approach for
any patient with LBBB after TAVI. This approach is justified by a
study by Rivard et al, who showed that prolongation of the HV-
interval and HAVB after TAVI can be observed also in patients
withpre-existing LBBB.16Different typesof valveswere included
in the study, making the population on the one hand more
heterogeneous, but on theother hand the resultsmore generally
admissible. We did not perform detailed electrophysiology
testing including pacing maneuvers to characterize conduction
behavior, but only a simple averaged HV-interval measurement.
However, in clinical practice, this simplified approach might
allow application even in interventional cardiology laboratories
without dedicated electrophysiology and pacing systems.
Conclusions
The proposed approach of measuring the HV-interval in
patients with LBBB after TAVI is feasible and safe. It
effectively identifies patients with LBBB who will not require
pacemaker implantation because of HAVB. Whether this may
prevent cardiac syncope in a general TAVI population with
LBBB needs further confirmation.
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Table S1. Univariate logistic regression analysis. 
Parameter Odds Ratio  
(OR) (95%CI) 
p-value 
   
Age [years] 1.095 (0.971-1.255) 0.151 
Male sex 0.663 (0.127-2.938) 0.786 
BMI [kg/m2] 1.050 (0.945-1.165) 0.358 
Hypertension 0.803 (0.183-3.774) 0.987 
CAD 0.836 (0.190-3.674) 0.999 
Diabetes 0.605 (0.056-3.548) 0.858 
Diagnosed AF 0.726 (0.138-3.231) 0.898 
PR interval [ms]  1.009 (0.992-1.026) 0.296 
QRS duration [ms] 0.987 (0.945-1.028) 0.536 
HV intervall [ms] 1.111 (1.039-1.204) 0.0013 
AF, atrial fibrillation; BMI, body mass index; CAD, coronary artery disease; HT, hypertension. 
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